Skip to main content
Ependymoma Intelligence Hub

Navigating Ependymoma,
Together.

Making up ~5% of adult and ~10% of pediatric CNS tumors, ependymoma remains an active area of molecular research. This platform was built to make clinical trial information accessible to every patient and caregiver.

Free forever · Written for patients & families · No medical jargon

Ependymoma Intelligence Hub
Live research field · updated hourly
157Studies tracked
2,500Sources monitored
24/7Live analysis

ClinicalTrials.gov, PubMed, the FDA and thousands of medical sources — read continuously, scored for Ependymoma relevance.

Continuously classified · relevance-scored
How we work

How we keep you informed

We read thousands of global medical sources around the clock, analyse new studies as they emerge, and translate the complex ones into clear, everyday language — so what matters reaches you without the noise.

01

We monitor

Continuously scanning ClinicalTrials.gov, PubMed, the FDA and thousands of sources for new Ependymoma-relevant research.

02

We analyse

Every study is classified, scored for relevance, and enriched with molecular markers and treatment data.

03

You discover

Browse an intelligence dashboard, explore active trials, or read a curated brief — all in clear, everyday language.

Why Zyntha

The information exists.
Now it’s yours.

We use technology to accelerate clinical trials efficiently, bring new treatments to patients faster, and work toward improving outcomes for every ependymoma patient.

Built specifically for the Ependymoma community — every study written for patients and families, updated within hours.

Why this platform

What makes this different

Written without the jargon

Every study, trial, and article is summarised so patients and families can actually understand it.

Updated continuously

Running 24/7 across thousands of sources. New trials and publications appear within hours — not weeks.

Designed for Ependymoma

Built for one community. Every feature — from molecular markers to subtype filters — speaks your language.

Trusted sources

Sourced from the world’s leading institutions

All content comes from peer-reviewed journals, verified trial registries, and top cancer research centres.

ClinicalTrials.govPubMedThe Lancet OncologyNature MedicineFDANCINeuro-OncologyASCOMD AndersonDana-FarberMemorial Sloan KetteringJAMA +108 more

Every article is scored for ependymoma relevance, classified by WHO grading criteria, and summarized in patient-friendly language before it reaches you.

We are not medical professionals. This platform is for educational and research purposes only — always consult your healthcare team for treatment decisions.

EPENDYMOMA INTELLIGENCE BRIEF

The research that matters, in your inbox every other week.

Stay informed, not overwhelmed

Sign up to receive the latest ependymoma research updates in your inbox. A bi-weekly jargon-free digest, for patients, caregivers, and researchers.

Free forever. Unsubscribe anytime. No spam, ever.